glp 1 and eyes GLP-1s are changing bodies… but what about the eyes? 👀 Here's what the current research shows: ▫ Rapid A1C reduction can trigger early worsening of DR (especially in moderate+ NPDR) ▫ More GLP-1 receptor agonists in eye

The effects of L-Carnitine supplementation in muscle cramp patients were studied in the Clinical Neuropharmacology journal (Bachman et al., 1996)

In summary , to treatment with GLP1-RAs compared with placebo or active controls was associated with increased risk of the composite outcome of gallbladder or biliary diseases and for cholelithiasis, cholecystitis, and biliary diseases

In type 2 diabetes mellitus (T2DM) , the incretin effect is diminished or absent, contributing to impaired insulin secretion

The well-established pathophysiological factors include visceral hypersensitivity (Simrn et al., 2018), altered gastrointestinal (GI) motility (Manabe et al., 2010